Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer

NCT00362882 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

81

Enrollment

NIH

Sponsor class

Conditions

Non-small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions

DRUG: docetaxel
DRUG: bortezomib
OTHER: laboratory biomarker analysis
OTHER: immunoenzyme technique
OTHER: immunohistochemistry staining method
OTHER: pharmacological study

Sponsor

National Cancer Institute (NCI)